These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 875120)

  • 21. [Effect of bromocriptine on prolactin secretion after dopaminergic receptor blockade with metoclopramide in patients with prostatic cancer treated with estrogens].
    Baranowska B; Szymanowski J; Jeske W
    Endokrynol Pol; 1984; 35(4):211-7. PubMed ID: 6510364
    [No Abstract]   [Full Text] [Related]  

  • 22. The adrenal cortex and prostatic cancer.
    Peeling WB; Griffiths K
    Proc R Soc Med; 1974 Nov; 67(11):1156-8. PubMed ID: 4438298
    [No Abstract]   [Full Text] [Related]  

  • 23. [Drug therapy of metastasizing prostate carcinoma with special reference to the bioavailability of fosfestrol after oral administration].
    Oelschläger H; Rothley D; Dunzendorfer U
    Arzneimittelforschung; 1988 Oct; 38(10):1502-12. PubMed ID: 3058134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormone therapy in cancer.
    Kennedy BJ
    Geriatrics; 1970 Oct; 25(10):106-12. PubMed ID: 4096937
    [No Abstract]   [Full Text] [Related]  

  • 25. [Severe acute thrombosis induced by high dosage of estrogen therapy].
    Danis RK; Lasry G; Melliere D; Beaumont V; Botto H
    Nouv Presse Med; 1978 Jul 1-8; 7(27):2396. PubMed ID: 673816
    [No Abstract]   [Full Text] [Related]  

  • 26. Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma.
    Geller J
    Urol Clin North Am; 1991 Feb; 18(1):83-91. PubMed ID: 1825145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Long-term study of plasma testosterone levels in hormone therapy of prostatic cancer].
    Hájek J; Hanselová M; Vrubel F
    Vnitr Lek; 1981 Sep; 27(9):852-60. PubMed ID: 7293030
    [No Abstract]   [Full Text] [Related]  

  • 28. [A case of advanced prostatic cancer presenting as inguinal mass].
    Ikeda K; Niwa N; Oka F; Ito H; Abe H; Nakagami Y
    Hinyokika Kiyo; 1991 Jul; 37(7):765-7. PubMed ID: 1927782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hormone therapy for prostatic carcinoma and hypertrophy].
    Hanschke HJ
    Dtsch Med Wochenschr; 1969 Mar; 94(13):677-8. PubMed ID: 4180637
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of prostatic carcinoma with Stilbostat.
    Zimel H; Bocancea D
    Neoplasma; 1974; 21(1):101-8. PubMed ID: 4596007
    [No Abstract]   [Full Text] [Related]  

  • 31. Progynon, a depot preparation with oestrogenic action, in the treatment of prostatic carcinoma.
    Birke G; Wadström LB
    Acta Chir Scand; 1965 Oct; 130(4):388-92. PubMed ID: 5842513
    [No Abstract]   [Full Text] [Related]  

  • 32. Paraparesis due to metastatic prostatic cancer effectively treated with a high dose of diethylstilbestrol diphosphate: a case report.
    Wakisaka M; Takagishi H
    Hinyokika Kiyo; 1993 Nov; 39(11):1055-8. PubMed ID: 8266876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
    Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
    J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone.
    Kris MG; Gralla RJ; Clark RA; Tyson LB; Fiore JJ; Kelsen DP; Groshen S
    Cancer Treat Rep; 1985 Nov; 69(11):1257-62. PubMed ID: 3912039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Orbital metastasis of a prostatic cancer. A therapeutic emergency].
    Aubert J; Dore B; Bon D
    Prog Urol; 1997 Feb; 7(1):81-4. PubMed ID: 9116744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of poor prognostic patients with advanced prostatic carcinoma with the association of diethylstilbestrol and cyclophosphamide.
    Germá Lluch JR; Marcuello Gaspar E; de Andrés Basauri L; López Pousa A; López López JJ
    Rev Esp Oncol; 1982; 29(2):317-24. PubMed ID: 7188232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective control of cisplatin induced emesis by combination drug regimen.
    Misra R; Agarwal N
    Indian J Cancer; 1994 Mar; 31(1):19-22. PubMed ID: 8063331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Honvan-high-dose therapy of prostatic carcinoma with metastases: early complications and value of prophylaxis against thrombosis].
    Heinz A; Meyer WW; Hallwachs O
    Urologe A; 1982 Jul; 21(4):232-4. PubMed ID: 6890263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemohormonal therapy of metastatic prostate cancer. A pilot study.
    Citrin DL; Hogan TF; Davis TE
    Cancer; 1983 Aug; 52(3):410-4. PubMed ID: 6861082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.